The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib

Cancer Chemotherapy and Pharmacology
Francesco GrossiPaolo Pronzato

Abstract

Recent studies have demonstrated that erlotinib therapy may be considered an option for patients with advanced non-small-cell lung cancer who experienced disease progression after treatment with gefitinib, particularly in patients in whom the disease had been stabilized for a long time prior to gefitinib therapy. The aim of this study was to evaluate the disease control rate and toxicity of gefitinib in patients whose disease progressed after erlotinib therapy. From May 2005 to August 2006, 15 patients received a 250 mg/day dosage of gefitinib after having disease progression while taking erlotinib at a dose of 150 mg/day. Among patients who received erlotinib, 1 (7%) achieved a partial response (PR), and 5 (33%) achieved stable disease (SD). Among patients who received gefitinib, none achieved a PR, and 6 achieved SD (40%). Five out of 6 patients who achieved PR/SD with erlotinib also achieved SD with gefitinib; 8 out of 9 patients who achieved a progressive disease (PD) with erlotinib also achieved a PD with gefitinib. The median time to progression (TTP) and overall survival (OS) were 2.3 and 3.5 months, respectively. The TTP and OS in SD patients were 3.7 and 7.4 months, respectively. The most common toxicities of gefitinib...Continue Reading

References

Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HidalgoE K Rowinsky
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José Baselga, Carlos L Arteaga
May 12, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pasi A JänneBruce E Johnson
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jan 13, 2006·Nature Clinical Practice. Oncology·Nicholas W ChoongPatrick C Ma
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea BezjakUNKNOWN National Cancer Institute of Canada Clinical Trials Group Study BR.21
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Byoung Chul ChoJoo Hang Kim
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory J RielyVincent A Miller
Apr 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Alvin S WongRoss A Soo
Jul 23, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D H LeeJ-S Lee
Aug 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Enrico VasileAlfredo Falcone
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel B CostaSusumu Kobayashi
Dec 27, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sung Hoon SimYung-Jue Bang
Mar 27, 2009·Cancer Chemotherapy and Pharmacology·Zheng-Tao ZhouCai-Hong Wen
Jun 23, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Kyoichi KairaNobuyuki Yamamoto
Aug 15, 2009·Cancer Chemotherapy and Pharmacology·Matthew K WongJames C Ho
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Aug 21, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tatsuya KatayamaTetsuya Mitsudomi
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Jan 29, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Kazuhiro AsamiKyoichi Okishio
Mar 8, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yosuke TogashiMichiaki Mishima
May 3, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Akito HataTadashi Ishida

❮ Previous
Next ❯

Citations

Jul 3, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fabio ConfortiTommaso Martino De Pas
Dec 7, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·S CarreraG L Vivanco
Mar 22, 2014·Expert Opinion on Pharmacotherapy·Carlo GenovaFrancesco Grossi
Feb 1, 2015·Journal of the American Academy of Dermatology·Johannah ValentineMario E Lacouture
Nov 11, 2015·The Korean Journal of Internal Medicine·Kyoung Min ChoDae Seog Heo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Byoung Chul ChoJoo Hang Kim
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Enrico VasileAlfredo Falcone
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Alvin S WongRoss A Soo
© 2022 Meta ULC. All rights reserved